ROCKVILLE, Md.--(BUSINESS WIRE)--Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced a publication describing a genetic polymorphism in the gene encoding the myeloid IgA Fc receptor, the FCAR Asp92Asn polymorphism, associated with increased risk for myocardial infarction (MI) and coronary heart disease (CHD).
